Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18680187 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES | May 2024 | May 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18645942 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18645951 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18645961 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | April 2024 | October 2024 | Allow | 6 | 1 | 1 | No | No |
| 18641205 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18438342 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18499857 | ADOPTIVE CELL TRANSFER AND ONCOLYTIC VIRUS COMBINATION THERAPY | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18385879 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | October 2023 | August 2024 | Allow | 10 | 2 | 1 | Yes | No |
| 18462340 | RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE | September 2023 | October 2024 | Allow | 13 | 0 | 0 | No | No |
| 18242025 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | September 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18339553 | METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS | June 2023 | April 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18329441 | NEUTRALIZING ANTIBODY IMMUNOASSAYS | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18327882 | CORONAVIRUS VACCINE | June 2023 | September 2023 | Allow | 4 | 3 | 0 | Yes | No |
| 18142988 | AAV CAPSID PRODUCTION IN INSECT CELLS | May 2023 | April 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18308934 | HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION | April 2023 | April 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18181974 | Separation Method | March 2023 | June 2025 | Allow | 28 | 2 | 0 | No | No |
| 18098949 | SAPONIN PURIFICATION | January 2023 | October 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18085110 | VIRUS PURIFICATION AND FORMULATION PROCESS | December 2022 | January 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18052178 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | November 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18051819 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | November 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17970036 | COMPOSITIONS AND METHODS FOR DELIVERY OF AAV | October 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 17869306 | HCoV IMMUNOGENIC BOOSTER COMPOSITION FOR IMPROVING IMMUNITYAGAINST SARS-COV-2 INFECTION | July 2022 | October 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17857303 | Virus-Like Particle Conjugates | July 2022 | January 2025 | Allow | 31 | 1 | 0 | No | No |
| 17856774 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | July 2022 | October 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17851492 | SAPOVIRUS VACCINES | June 2022 | June 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17839401 | HUMAN CYTOMEGALOVIRUS VACCINE | June 2022 | October 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17837294 | COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER | June 2022 | April 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17709599 | COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY | March 2022 | July 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17642795 | LASSAVIRUS VACCINES | March 2022 | May 2025 | Allow | 38 | 0 | 0 | No | No |
| 17575462 | USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS | January 2022 | April 2025 | Allow | 40 | 3 | 0 | Yes | No |
| 17609217 | INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONS | November 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17512246 | SYSTEMS AND METHODS FOR ULTRA-SPECIFIC AND ULTRA-SENSITIVE NUCLEIC ACID DETECTION | October 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17487690 | MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS | September 2021 | July 2024 | Allow | 34 | 1 | 1 | No | No |
| 17442871 | IMMUNOCHROMATOGRAPHIC ASSAY METHOD, AND TEST STRIP USED IN SAID IMMUNOCHROMATOGRAPHIC ASSAY METHOD | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17478537 | Compositions and Methods for Dengue Virus Chimeric Constructions in Vaccines | September 2021 | May 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17404143 | Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using Same | August 2021 | October 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17401079 | Rapid Viral Diagnostic Test | August 2021 | April 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17386644 | VIRAL VECTOR ASSAY AND VECTOR | July 2021 | November 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17385416 | THERMAL INACTIVATION OF ROTAVIRUS | July 2021 | March 2025 | Abandon | 44 | 2 | 1 | Yes | No |
| 17372044 | BOVINE HERPESVIRUS TYPE 1 (BOHV-1) VECTOR AGAINST BOVINE RESPIRATORY DISEASE COMPLEX | July 2021 | January 2025 | Allow | 42 | 2 | 0 | No | No |
| 17357368 | VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES | June 2021 | February 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17246364 | VIRAL SEROLOGY ASSAYS | April 2021 | July 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17232751 | NANO-SATELLITE COMPLEXES | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17276788 | CORONAVIRUS VACCINE | March 2021 | November 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 17172300 | COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF | February 2021 | January 2025 | Abandon | 47 | 4 | 1 | No | No |
| 17266049 | RECOMBINANT BIOLOGICALLY CONTAINED FILOVIRUS VACCINE | February 2021 | January 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 16972077 | ANTIBODIES OR ANTIBODY-FRAGMENTS THEREOF TARGETING ALPHAVIRUSES, AND COMPOSITIONS AND METHODS COMPRISING SAME | December 2020 | August 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17059882 | TARGETING P18 FOR mTOR-RELATED DISORDERS | November 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17097687 | METHOD FOR DETERMINING THE SENSITIVITY OF A BACTERIAL STRAIN TO A BACTERIOPHAGE | November 2020 | December 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 17047611 | BACTERIOPHAGE COMPOSITIONS | October 2020 | February 2025 | Allow | 52 | 3 | 1 | No | No |
| 17040455 | IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODS | September 2020 | August 2024 | Allow | 47 | 1 | 1 | No | No |
| 16981197 | SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES | September 2020 | February 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 16976220 | ATTENUATED FLAVIVIRUSES | August 2020 | August 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16755257 | MAYARO VIRUS CONSENSUS ANTIGENS, DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MAYARO VIRUS, AND COMBINATIONS THEREOF | April 2020 | September 2024 | Allow | 53 | 6 | 1 | Yes | No |
| 16172487 | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS | October 2018 | January 2019 | Allow | 3 | 1 | 0 | No | No |
| 16047524 | RSV-SPECIFIC BINDING MOLECULE | July 2018 | March 2020 | Allow | 20 | 1 | 1 | Yes | No |
| 15682341 | METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES | August 2017 | November 2024 | Abandon | 60 | 9 | 0 | Yes | No |
| 15545337 | ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF | July 2017 | April 2020 | Allow | 33 | 2 | 1 | Yes | No |
| 15605745 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | May 2017 | June 2018 | Allow | 12 | 0 | 0 | No | No |
| 15523899 | METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT | May 2017 | April 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15404662 | MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS | January 2017 | April 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15315687 | METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS | December 2016 | December 2019 | Allow | 36 | 2 | 2 | Yes | No |
| 15315667 | METHOD FOR RAPID GENERATION OF AN INFECTIOUS RNA VIRUS | December 2016 | April 2019 | Allow | 29 | 1 | 1 | Yes | No |
| 15204077 | DNA VACCINE AGAINST VIRUS OF YELLOW FEVER | July 2016 | April 2018 | Allow | 21 | 1 | 0 | Yes | No |
| 15032338 | LIVE ATTENUATED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) VACCINES AND PREPARATION THEREOF | April 2016 | September 2018 | Allow | 29 | 2 | 1 | No | No |
| 15132436 | Pestivirus Species | April 2016 | April 2018 | Allow | 24 | 1 | 1 | Yes | No |
| 14935281 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS | November 2015 | February 2018 | Allow | 28 | 2 | 0 | Yes | No |
| 14652066 | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES FOR TRIVALENT DENGUE VIRUS FORMULATIONS | June 2015 | September 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14439967 | EFFECT OF HBV ON CLINICAL OUTCOME OF HEPATOCELLULAR CARCINOMA CANCER PATIENTS | April 2015 | January 2018 | Allow | 33 | 4 | 0 | No | No |
| 14429559 | VIRUSES ASSOCIATED WITH IMMUNODEFICIENCY AND ENTEROPATHY AND METHODS USING SAME | March 2015 | February 2017 | Allow | 23 | 1 | 1 | Yes | No |
| 14407012 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS | December 2014 | March 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14400642 | CROSS-REACTIVE ANTIBODIES AGAINST DENGUE VIRUS AND USES THEREOF | November 2014 | September 2016 | Allow | 22 | 1 | 1 | Yes | No |
| 14182731 | NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS | February 2014 | March 2016 | Allow | 25 | 1 | 1 | Yes | No |
| 14165126 | T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION | January 2014 | April 2016 | Allow | 26 | 1 | 1 | Yes | No |
| 14090221 | ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS | November 2013 | April 2016 | Allow | 29 | 2 | 0 | No | No |
| 14039148 | RSV SPECIFIC BINDING MOLECULE | September 2013 | October 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 14036412 | PESTIVIRUS SPECIES | September 2013 | January 2016 | Allow | 28 | 2 | 1 | No | No |
| 13984702 | COMBINATION OF BIOMARKERS FOR THE DETECTION AND EVALUATION OF HEPATITIS FIBROSIS | August 2013 | December 2016 | Allow | 40 | 3 | 1 | No | No |
| 13942064 | RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORS | July 2013 | August 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 13825049 | RECOMBINANT FLAVIVIRAL CONSTRUCTS AND USES THEREOF | June 2013 | May 2015 | Allow | 26 | 2 | 0 | Yes | No |
| 13740100 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES | January 2013 | May 2015 | Allow | 28 | 3 | 0 | Yes | No |
| 13633436 | Replication-Defective Flavivirus Vaccines and Vaccine Vectors | October 2012 | August 2015 | Allow | 34 | 2 | 1 | Yes | No |
| 13504464 | DNA VACCINE AGAINST VIRUS OF YELLOW FEVER | August 2012 | March 2016 | Allow | 46 | 2 | 1 | Yes | Yes |
| 13492884 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS | June 2012 | October 2014 | Allow | 28 | 2 | 1 | Yes | No |
| 13406153 | RECOMBINANT FLAVIVIRUS VACCINES | February 2012 | June 2014 | Allow | 28 | 2 | 1 | Yes | No |
| 13321460 | Compositions And Methods For The Therapy And Diagnosis Of Influenza | February 2012 | January 2014 | Allow | 26 | 2 | 1 | Yes | No |
| 13357189 | NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUS | January 2012 | August 2015 | Allow | 43 | 2 | 1 | No | No |
| 13309498 | MULTI PLASMIDS SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS | December 2011 | November 2012 | Allow | 12 | 1 | 0 | No | No |
| 13274285 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES | October 2011 | January 2014 | Allow | 27 | 5 | 0 | Yes | No |
| 13230209 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION | September 2011 | April 2014 | Allow | 31 | 2 | 1 | No | No |
| 13130554 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 | September 2011 | August 2014 | Allow | 39 | 2 | 1 | Yes | No |
| 13130559 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 | September 2011 | August 2014 | Allow | 39 | 2 | 1 | Yes | No |
| 13199348 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof | August 2011 | August 2014 | Allow | 35 | 1 | 0 | No | No |
| 13190547 | Assay for the diagnosis of flaviviral infection using antibodies with high affinity for NS1 protein of flavivirus in hexameric form | July 2011 | December 2013 | Allow | 28 | 4 | 1 | Yes | No |
| 13102685 | DENGUE CHIMERIC VIRUSES | May 2011 | March 2012 | Allow | 11 | 0 | 1 | Yes | No |
| 12995024 | EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF | January 2011 | June 2015 | Allow | 54 | 6 | 1 | Yes | No |
| 12922513 | REPLICATION-DEFECTIVE FLAVIVIRUS VACCINES AND VACCINE VECTORS | December 2010 | April 2014 | Allow | 43 | 2 | 1 | No | No |
| 12956460 | FLAVIVIRUS FUSION INHIBITORS | November 2010 | December 2011 | Allow | 12 | 1 | 1 | Yes | No |
| 12809345 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1B | November 2010 | June 2013 | Allow | 36 | 1 | 1 | Yes | No |
| 12808565 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 6A | November 2010 | June 2013 | Allow | 36 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, STACY BROWN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 39.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHEN, STACY BROWN works in Art Unit 1671 and has examined 279 patent applications in our dataset. With an allowance rate of 92.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner CHEN, STACY BROWN's allowance rate of 92.8% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, STACY BROWN receive 2.28 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +7.1% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 37% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 29.8% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 59.4% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 91.4% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 71.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.4% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 25.8% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.